Korea Pharma한국파마
032300 · KOSDAQ · ₩032300 · 한국파마
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩5,589
vs the current price (₩8,170)
- Enterprise value
- ₩61B
- Equity value
- ₩61B
- WACC
- 7.4%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Bear / Base / Bull
- Bear
- ₩2,555
- −68.7%
- Base
- ₩5,589
- −31.6%
- Bull
- ₩11,020
- +34.9%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (5.8%).
Revenue growth
- 2.6%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 2.7%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 2.8%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 2.9%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (2.6% a year, annual reports), fading to 3% by year 5.
Business
- 5.8%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 2.6%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 3.1%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 26.3%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.11%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-28.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.24, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.61%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩94B
- Net debt (borrowings and leases − cash and deposits)
- ₩373M
- + Stakes and investments
- ₩204M
- Associates, long-term financial assets and deposits (book value)
- Shares
- 10,906,701
- Share price
- ₩8,170
- Market cap
- ₩89B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩83B | ₩81B | ₩88B | ₩96B | ₩99B | ₩102B | ₩105B | ₩108B |
| Growth | 2.7% | −2.4% | 7.8% | 2.6% | 2.7% | 2.8% | 2.9% | 3.0% |
| EBIT | ₩6.3B | ₩6.1B | −₩887M | ₩5.6B | ₩5.7B | ₩5.9B | ₩6.1B | ₩6.3B |
| EBIT margin | 7.5% | 7.5% | −1.0% | 5.8% | 5.8% | 5.8% | 5.8% | 5.8% |
| After-tax EBIT | ₩4.5B | ₩4.4B | −₩643M | ₩4.1B | ₩4.2B | ₩4.3B | ₩4.4B | ₩4.5B |
| + Depreciation | ₩2.2B | ₩2.1B | ₩2.3B | ₩2.5B | ₩2.6B | ₩2.6B | ₩2.7B | ₩2.8B |
| − Capital spending | ₩2.7B | ₩3.8B | ₩1.3B | ₩3B | ₩3.1B | ₩3.2B | ₩3.2B | ₩3.3B |
| − Working capital | ₩8.9B | −₩9.2B | −₩1.7B | ₩642M | ₩684M | ₩729M | ₩776M | ₩826M |
| Free cash flow | −₩4.9B | ₩12B | ₩2.1B | ₩2.9B | ₩3B | ₩3B | ₩3.1B | ₩3.2B |
| Discount factor | — | — | — | 0.931 | 0.867 | 0.807 | 0.752 | 0.700 |
| Present value | — | — | — | ₩2.7B | ₩2.6B | ₩2.5B | ₩2.3B | ₩2.2B |
Terminal value ₩70B, worth ₩49B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩6,750 a share)Now 1.21× | ₩11,8801.76× | ₩20,6643.06× | ₩43,2156.40× |
| P/E on run-rate earnings (Q2 2026 × 4: ₩235 a share)Now 34.8× | ₩9,76841.6× | ₩13,88859.1× | ₩16,08068.4× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.4% | ₩6,146 | ₩6,486 | ₩6,902 | ₩7,422 | ₩8,092 |
| 6.9% | ₩5,600 | ₩5,863 | ₩6,178 | ₩6,563 | ₩7,044 |
| 7.4% | ₩5,140 | ₩5,346 | ₩5,589 | ₩5,880 | ₩6,235 |
| 7.9% | ₩4,747 | ₩4,911 | ₩5,100 | ₩5,324 | ₩5,591 |
| 8.4% | ₩4,408 | ₩4,539 | ₩4,688 | ₩4,862 | ₩5,067 |
Now (TTM)
- Market cap
- ₩89B
- Enterprise value
- ₩89B
- P/E
- —
- P/B
- 1.2×
- P/S
- 0.9×
- EV/EBITDA
- 23.0×
- Dividend yield
- 0.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩13,000 | ₩15,310 | ₩23,650 | ₩21,400 | ₩48,550 |
| Market cap | ₩142B | ₩167B | ₩258B | ₩233B | ₩530B |
| P/E | — | 44.0× | 3,079.4× | — | 83.1× |
| P/B | 2.1× | 2.3× | 3.8× | 3.9× | 9.2× |
| P/S | 1.6× | 2.1× | 3.1× | 2.9× | 6.7× |
| EV/EBITDA | 107.4× | 18.4× | 29.7× | 27.5× | 75.2× |
| Dividend yield | 0.0% | — | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Korea Pharma | — | 1.2× | 0.9× | 23.0× | 0.0% |
| Samsung Biologics | 32.0× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.9× | 2.5× | 9.0× | — | 0.0% |
| Alteogen | 80.5× | 29.0× | 61.2× | — | 0.1% |
| SK biopharmaceuticals | 14.7× | 5.8× | 6.8× | — | 0.0% |
| Yuhan | 24.0× | 2.4× | 2.5× | 31.3× | 0.8% |
| HLB | — | 15.7× | 55.6× | — | 0.0% |
| Similar companies (median) | 27.9× | 6.7× | 11.5× | 31.3× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Korea Pharma / 한국파마 / 032300 / KRX:032300
Source: KRX statistical information